Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




A Rapid Method for Isolating Viral DNA-enriched Salivary Exosomes for Diagnosis and Monitoring of Oropharyngeal Cancer

By LabMedica International staff writers
Posted on 24 Dec 2019
A novel method, based on the combination of microfluidics and acoustics, for concentrating exosomes containing viral DNA from the saliva of oropharyngeal cancer patients was found to be 15 times more sensitive than the current gold standard differential centrifugation method.

Previous efforts to evaluate the detection of human papilloma viral (HPV) DNA in whole saliva as a diagnostic measure for HPV-associated oropharyngeal cancer (HPV-OPC) did not demonstrate sensitivity sufficient for routine clinical use. More...
In this regard, investigators at Duke University (Durham, NC, USA) hypothesized that salivary exosomes were packaged with HPV-associated biomarkers, and efficient enrichment of salivary exosomes through isolation would enhance diagnostic and prognostic performance for HPV-OPC.

Exosomes are cell-derived vesicles that are present in many and perhaps all biological fluids, including blood, urine, and cultured medium of cell cultures. The reported diameter of exosomes is between 30 and 100 nanometers, which is larger than low-density lipoproteins but much smaller than red blood cells. Exosomes, which contain RNA, proteins, lipids, and metabolites that are reflective of the cell type of origin, are either released from the cell when multivesicular bodies (MVBs) fuse with the plasma membrane, or they are released directly from the plasma membrane. Exosomes have specialized functions and play a key role in coagulation, intercellular signaling, and waste management.

To generate samples enriched with salivary exosomes, the investigators developed an acoustofluidic (the fusion of acoustics and microfluidics) platform. The minute acoustofluidic chip removed unwanted particles based on size, leaving exosome-rich concentrated samples that facilitated detection of tumor-specific biomarkers. The automated and fast exosome isolation (less than five minutes of processing time compared to approximately eight hours of processing time using benchmark technologies) could be performed at relatively low cost and was suitable for repeated and continuous monitoring of tumor progression and treatment.

The investigators used the acoustofluidic system to analyze saliva samples from 10 patients diagnosed with HPV-OPC using traditional methods. They found that the platform was capable of consistently isolating exosomes from saliva samples, regardless of viscosity variation and collection method. Compared with the current gold standard, differential centrifugation, droplet digital RT-PCR analysis showed that the average yield of salivary exosomal small RNA from the acoustofluidic platform was 15 times higher. With this high-yield exosome isolation platform, they showed that HPV16 DNA could be detected in isolated exosomes from the saliva of HPV-associated OPC patients at 80% concordance with tissues/biopsies positive for HPV16.

"OPC has an approximate incidence of 115,000 cases per year worldwide and is one of the fastest-rising cancers in Western countries due to increasing HPV-related incidence, especially in younger patients. It is paramount that surveillance methods are developed to improve early detection and outcomes," said senior author Dr. Tony Jun Huang, professor of mechanical engineering and materials science at Duke University. "Considering these factors, the successful detection of HPV from salivary exosomes isolated by our acoustofluidic platform offers distinct advantages, including early detection, risk assessment, and screening. This technique may also help physicians predict which patients will respond well to radiation therapy or achieve longer progression-free survival."

The acoustofluidic method was described in the December 13, 2019, online edition of the Journal of Molecular Diagnostics.

Related Links:
Duke University


New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Serological Pipet Controller
PIPETBOY GENIUS
New
Silver Member
Quality Control Material
NATtrol Chlamydia trachomatis Positive Control
New
Automated PCR Setup
ESTREAM
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.